2023-08-02

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting​

Our Focus

Our Focus Gastrointestinal Cancers Gastrointestinal cancers presents a pressing challenge marked by unmet medical needs. Stomach, pancreas, colon, bile duct, and liver cancers collectively bear a significant burden, characterized by their high mortality rates and limited treatment alternatives. The complexity of these malignancies demands a new era of innovative therapeutic interventions that can effectively target the intricate molecular pathways driving […]

Management Team

Arbele is founded by scientists and senior executives with vast experience from biotech and pharmaceutical industries, and is supported by highly capable legal, and financial professionals

About Arbele

Arbele’s mission is to create more effective treatments for GI cancers

Social Impact

Our business is to maximize availability of more effective cancer treatments for greater global health

Health Enhancement

To deliver “combination” immunotherapeutics possessing multiple anti-tumor mechanisms that are curative, or substantially prolong survival and improve quality of life

Breakthrough Innovation

Data driven research and proprietary discovery platforms to develop the safest products with the highest therapeutic potential

error: Content is protected !!